Much of this decline can be attributed to the company’s weaker-than-expected performance ... citing issues with a third-party supplier. Given the substantial fall in Regeneron’s stock price ...

Despite these setbacks, Regeneron’s overall financial performance remained resilient ... to near-term earnings growth potential, the stock appears undervalued according to InvestingPro ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ... relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the ...

My last analysis on REGN noted that the stock is priced for ~3% revenue growth ... Resolving Eylea HD PFS and extended dosing issues should help, but Regeneron's leading position is spoiled.

The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The S&P 500 climbed 0.7% on Tuesday, May 13, 2025, bringing the index into positive territory for the year as investors ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Verizon ...

The outbreak occurred in a flock of 190 backyard poultry birds in the district of Birzgales, Paris-based WOAH said in a notice, citing Latvian authorities. Vera shares skyrocket as kidney disease drug ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...